New therapies such as sodium-glucose co-transporter 2 inhibitors (SGLT2), which inhibit renal glucose reabsorption and cause glucosuria, favor candida colonization and candiduria [14,24]. This evidence concerns the gene SLC5A2 and Glycosuria.